NASDAQ:SEEL

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

$0.63

+0.05 (+7.75%)

(As of 05/20/2022 04:00 PM ET)

Add

Compare

Today's Range: $0.58
▼
$0.63
50-Day Range: $0.51
▼
$0.96
52-Week Range: $0.48
▼
$3.59

Volume: 966,900 shs
Average Volume: 1.66 million shs
Market Capitalization: $66.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Beta: 2.62

30 days | 90 days | 365 days | Advanced Chart

Receive SEEL News and Ratings via Email

Sign-up to receive the latest news and ratings for Seelos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Seelos Therapeutics

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

May 18, 2022 | seekingalpha.com

Seelos Therapeutics to get US patent for SLS-007 linked to treating neurodegenerative diseases

May 18, 2022 | finance.yahoo.com

Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007

May 16, 2022 | americanbankingnews.com

Seelos Therapeutics (NASDAQ:SEEL) Upgraded at Zacks Investment Research

May 12, 2022 | finance.yahoo.com

Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference

May 11, 2022 | apnews.com

Seelos: Q1 Earnings Snapshot

May 9, 2022 | americanbankingnews.com

-$0.28 Earnings Per Share Expected for Seelos Therapeutics, Inc. (NASDAQ:SEEL) This Quarter

April 22, 2022 | finance.yahoo.com

Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference

April 18, 2022 | msn.com

Psychedelic Stock Gainers And Losers From April 18, 2022

April 14, 2022 | finanznachrichten.de

Microsmallcap.com: Why Psychedelics Could Soon Replace Antidepressants

April 11, 2022 | msn.com

Psychedelic Stock Gainers And Losers From April 11, 2022

April 11, 2022 | finance.yahoo.com

Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee

April 8, 2022 | msn.com

Revive Therapeutics, Cybin Among Top Psychedelic Movers Of Today

March 31, 2022 | msn.com

Field Trip Health, Revive Therapeutics Among Top Psychedelic Movers Of Today

See More Headlines

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SEEL
Previous Symbol
CUSIP: N/A
CIK: 1017491
Web: www.seelostherapeutics.com
Phone: (646) 293-2100
Fax: 858-436-8155
Employees: 15
Year Founded: N/A

Sales & Book Value

Annual Sales: $380 thousand
Price / Sales: 175.89
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.43 per share
Price / Book: 1.47

Profitability

EPS (Most Recent Fiscal Year): N/A
Net Income: $-66.05 million
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -91.66%
Return on Assets: -72.83%

Debt

Debt-to-Equity Ratio: 0.33
Current Ratio: 6.98
Quick Ratio: 6.98

Price-To-Earnings

Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A

Miscellaneous

Outstanding Shares: 106,091,000
Free Float: 100,680,000
Market Cap: $66.84 million
Optionable: Not Optionable

Company Calendar

Today: 5/22/2022
Next Earnings (Estimated): 8/08/2022
Fiscal Year End: 12/31/2022

MarketRank^™

Overall MarketRank^™

1.97 out of 5 stars

Medical Sector

632nd out of 1,416 stocks

Pharmaceutical Preparations Industry

289th out of 677 stocks

3.5 Analyst's Opinion

Consensus Rating
Seelos Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $7.50, Seelos Therapeutics has a forecasted upside of 1,090.5% from its current price of $0.63.
Amount of Analyst Coverage
Seelos Therapeutics has only been the subject of 1 research reports in the past 90 days.

4.7 Community Rank

Outperform Votes
Seelos Therapeutics has received 68 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Seelos Therapeutics has received 30 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Seelos Therapeutics has received 69.39% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote “Outperform” if you believe SEEL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Seelos Therapeutics does not currently pay a dividend.
Dividend Growth
Seelos Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Seelos Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $56,667.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of Seelos Therapeutics is held by insiders.
Percentage Held by Institutions
Only 38.73% of the stock of Seelos Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Seelos Therapeutics are expected to decrease in the coming year, from ($0.90) to ($1.03) per share.
Price to Book Value per Share Ratio
Seelos Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

Is Seelos Therapeutics a buy right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seelos Therapeutics stock.
View analyst ratings for Seelos Therapeutics or view top-rated stocks.
When is Seelos Therapeutics' next earnings date?: Seelos Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Seelos Therapeutics.
What price target have analysts set for SEEL?: 4 Wall Street analysts have issued 1-year price objectives for Seelos Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they anticipate Seelos Therapeutics' stock price to reach $7.50 in the next year. This suggests a possible upside of 1,090.5% from the stock's current price.
View analysts' price targets for Seelos Therapeutics or view top-rated stocks among Wall Street analysts.
Who are Seelos Therapeutics' key executives?: Seelos Therapeutics' management team includes the following people:
Dr. Raj Mehra J.D., Ph.D., Founder, Chairman, CEO & Pres (Age 62, Pay $921.12k)
Mr. Michael J. Golembiewski, Chief Financial Officer (Age 50, Pay $416.93k)
Ms. Kimberly Farrand, Sr. Director of Clinical Devel. & Operations
Mr. Anthony Marciano, Chief Communications Officer
Gopal Krishna Ph.D., Head of Manufacturing & Technical Operations
Tim Whitaker M.D., Chief Medical Officer
Who are some of Seelos Therapeutics' key competitors?: Some companies that are related to Seelos Therapeutics include Lexicon Pharmaceuticals (LXRX), LianBio (LIAN), AC Immune (ACIU), Precigen (PGEN), Ocular Therapeutix (OCUL), VBI Vaccines (VBIV), Provention Bio (PRVB), Silence Therapeutics (SLN), ESSA Pharma (EPIX), Alpine Immune Sciences (ALPN), MacroGenics (MGNX), Gracell Biotechnologies (GRCL), Immutep (IMMP), Verona Pharma (VRNA) and Verastem (VSTM).
View all of SEEL's competitors.
What other stocks do shareholders of Seelos Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Seelos Therapeutics investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Biocept (BIOC), Onconova Therapeutics (ONTX), Co-Diagnostics (CODX), Heat Biologics (HTBX), iBio (IBIO) and OPKO Health (OPK).
What is Seelos Therapeutics' stock symbol?: Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."
Who are Seelos Therapeutics' major shareholders?: Seelos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.96%), Vanguard Group Inc. (5.35%), Woodline Partners LP (2.65%), Mirae Asset Global Investments Co. Ltd. (1.83%), State Street Corp (1.65%) and Renaissance Technologies LLC (1.63%).
View institutional ownership trends for Seelos Therapeutics.
Which major investors are selling Seelos Therapeutics stock?: SEEL stock was sold by a variety of institutional investors in the last quarter, including Woodline Partners LP, Connacht Asset Management LP, BlackRock Inc., DAVENPORT & Co LLC, JPMorgan Chase & Co., Northern Trust Corp, Goldman Sachs Group Inc., and Group One Trading L.P..
View insider buying and selling activity for Seelos Therapeutics or view top insider-selling stocks.
Which major investors are buying Seelos Therapeutics stock?: SEEL stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Mirae Asset Global Investments Co. Ltd., Vanguard Group Inc., AdvisorShares Investments LLC, State Street Corp, Penserra Capital Management LLC, First Republic Investment Management Inc., and Citigroup Inc..
View insider buying and selling activity for Seelos Therapeutics or or view top insider-buying stocks.
How do I buy shares of Seelos Therapeutics?: Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Seelos Therapeutics' stock price today?: One share of SEEL stock can currently be purchased for approximately $0.63.
How much money does Seelos Therapeutics make?: Seelos Therapeutics has a market capitalization of $66.84 million and generates $380 thousand in revenue each year.
How many employees does Seelos Therapeutics have?: Seelos Therapeutics employs 15 workers across the globe.
What is Seelos Therapeutics' official website?: The official website for Seelos Therapeutics is www.seelostherapeutics.com.
How can I contact Seelos Therapeutics?: Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at (646) 293-2100, via email at [email protected], or via fax at 858-436-8155.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

About Seelos Therapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank^™

Overall MarketRank^™

3.5 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage

4.7 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

Dividend Yield

Dividend Growth

1.7 Company Ownership

Insider Buying vs. Insider Selling

Percentage Held by Insiders

Percentage Held by Institutions

0.0 Earnings and Valuation

Earnings Growth

Price to Book Value per Share Ratio

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Seelos Therapeutics (SEEL) Stock Forecast, Price & News

About Seelos Therapeutics

Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous

Company Calendar

MarketRank™

Overall MarketRank™

3.5 Analyst's Opinion

4.7 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

0.0 Dividend Strength

1.7 Company Ownership

0.0 Earnings and Valuation

Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

MarketRank^™

Overall MarketRank^™